Cubist Systematic Strategies’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$29.6M Sell
38,800
-13,100
-25% -$9.75M 0.14% 162
2025
Q2
$40.5M Buy
51,900
+6,700
+15% +$5.21M 0.19% 114
2025
Q1
$37.3M Buy
45,200
+20,200
+81% +$16.8M 0.23% 60
2024
Q4
$19.3M Sell
25,000
-400
-2% -$331K 0.12% 217
2024
Q3
$22.5M Buy
25,400
+23,700
+1,394% +$21.3M 0.14% 157
2024
Q2
$1.54M Sell
1,700
-31,600
-95% -$25.3M 0.01% 1491
2024
Q1
$25.9M Sell
33,300
-24,700
-43% -$17.6M 0.15% 119
2023
Q4
$33.8M Sell
58,000
-2,600
-4% -$1.52M 0.22% 46
2023
Q3
$32.6M Buy
60,600
+14,000
+30% +$7.21M 0.24% 44
2023
Q2
$21.9M Buy
46,600
+12,500
+37% +$5.24M 0.15% 106
2023
Q1
$11.7M Sell
34,100
-31,200
-48% -$10.5M 0.07% 382
2022
Q4
$23.9M Sell
65,300
-19,700
-23% -$6.98M 0.14% 102
2022
Q3
$27.5M Sell
85,000
-6,900
-8% -$2.19M 0.15% 70
2022
Q2
$29.8M Buy
+91,900
New +$27.6M 0.18% 46

Other funds holding LLY

Cubist Systematic Strategies's LLY Position: Q3 2025 in Review

Cubist Systematic Strategies increased its Eli Lilly (LLY) stake by 29% in Q3 2025, buying an estimated $2.33M and bringing the position to 13,889 shares worth $10.6M. The position accounts for 0.05% of the portfolio, ranked #530.

Cubist Systematic Strategies first reported a position in LLY in Q2 2014 and has held it in 42 quarters since. The position peaked at $40.6M in Q3 2024. 3,897 funds tracked by Wall St. Rank hold LLY as of Q3 2025.

  • Cubist Systematic Strategies held 13,889 shares of Eli Lilly worth $10.6M as of Q3 2025.
  • Cubist Systematic Strategies bought 3,128 Eli Lilly shares in Q3 2025, an estimated $2.33M.
  • Eli Lilly made up 0.05% of Cubist Systematic Strategies's portfolio in Q3 2025, its #530 holding.
  • Cubist Systematic Strategies first reported a position in Eli Lilly in Q2 2014 and has held it in 42 quarters since.
  • Cubist Systematic Strategies's Eli Lilly position peaked at $40.6M in Q3 2024.
  • 3,897 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.